Last reviewed · How we verify

Capsaicin Topical Cream

Women and Infants Hospital of Rhode Island · FDA-approved active Small molecule

Capsaicin activates TRPV1 pain receptors on nerve endings, causing initial stimulation followed by desensitization and depletion of substance P, reducing pain signal transmission.

Capsaicin activates TRPV1 pain receptors on nerve endings, causing initial stimulation followed by desensitization and depletion of substance P, reducing pain signal transmission. Used for Localized neuropathic pain (post-herpetic neuralgia, diabetic neuropathy), Musculoskeletal pain and arthritis, Topical pain relief.

At a glance

Generic nameCapsaicin Topical Cream
Also known asChili
SponsorWomen and Infants Hospital of Rhode Island
Drug classTopical analgesic; TRPV1 agonist
TargetTRPV1 (transient receptor potential vanilloid 1)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Capsaicin is a natural alkaloid that binds to and activates the transient receptor potential vanilloid 1 (TRPV1) channel on nociceptive nerve fibers. Repeated or sustained exposure leads to desensitization of these nerve endings and depletion of substance P, a key neurotransmitter in pain signaling, resulting in localized analgesia. This mechanism makes it effective for topical pain relief in conditions involving peripheral neuropathic or musculoskeletal pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: